This is the Q1 portfolio update of Carl Icahn's Icahn Capital Management LP. Carl Icahn likes to buy distressed situations. He is also a famed active investor, buy shares in a company and push for change. , he must see a lot of them these days. Carl Icahn owns 20 stocks with a total value of $2.3 billion. These are the details of the buys and sells.
Carl Icahn buys UltraShort Real Estate ProShares, sells Anadarko Petroleum Corp., TempleInland Inc., FORESTAR RE GROUP, AMICUS THERAPEUTICS, INC., LIFE TECHNOLOGIES CORPORATION during the 3-months ended 03/31/2009, according to the most recent filings of his investment company, Icahn Capital Management LP.
New Purchases: SRS,
Added Positions: AMLN, ENZN, LGF, TTWO,
Reduced Positions: ENDP, WMB,
Sold Out: APC, FOLD, FOR, LIFE, TIN,
For the details of Carl Icahn's stock buys and sells, go to the Link Here
This is the sector weightings of Carl Icahn's portfolio:
These are the top 5 holdings of Carl Icahn
Carl Icahn added to his holdings in Lions Gate Entertainment Corp. by 49.93%. His purchase prices were between $4.2 and $5.8, with an estimated average price of $5.2. The impact to his portfolio due to this purchase was 0.97%. His holdings were 13,432,899 shares as of 03/31/2009.
Lions Gate Entertainment is a leading diversified independent producer and distributor of motion pictures home entertainment television programming animation and video-on-demand content. Lions Gate Entertainment Corp. has a market cap of $618.6 million; its shares were traded at around $5.34 with and P/S ratio of 0.4.
Added: Amylin Pharmaceuticals Inc. (AMLN, Financial)
Carl Icahn added to his holdings in Amylin Pharmaceuticals Inc. by 13.52%. His purchase prices were between $8.41 and $13.44, with an estimated average price of $11.2. The impact to his portfolio due to this purchase was 0.78%. His holdings were 12,971,328 shares as of 03/31/2009.
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes SYMLIN injection and BYETTA injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego California with over one thousand five hundred employees nationwide. Amylin Pharmaceuticals Inc. has a market cap of $1.58 billion; its shares were traded at around $11.23 with and P/S ratio of 1.9.
Added: TakeTwo Interactive Software Inc. (TTWO, Financial)
Carl Icahn added to his holdings in TakeTwo Interactive Software Inc. by 270.97%. His purchase prices were between $6.19 and $8.57, with an estimated average price of $7.4. The impact to his portfolio due to this purchase was 0.53%. His holdings were 2,007,445 shares as of 03/31/2009.
Take-Two Interactive Software Inc. is a leading worldwide developer publisher and distributor of interactive software games. The company's software operates on multimedia personal computers and video game console platforms. They are one of the largest distributors of interactive software games in the United States and one of the top publishers of interactive software games in Europe. TakeTwo Interactive Software Inc. has a market cap of $751 million; its shares were traded at around $9.35 with a P/E ratio of 7.4 and P/S ratio of 0.5.
Added: Enzon Inc. (ENZN, Financial)
Carl Icahn added to his holdings in Enzon Inc. by 14.61%. His purchase prices were between $5.27 and $7.1, with an estimated average price of $6.1. The impact to his portfolio due to this purchase was 0.09%. His holdings were 2,816,861 shares as of 03/31/2009.
Enzon Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases. Enzon's specialized sales force markets ABELCET ONCASPAR ADAGEN and DEPOCYT in the United States. In addition Enzon also receives royalties on sales of PEG-INTRON marketed by Schering-Plough Corporation and MACUGEN marketed by OSI Pharmaceuticals and Pfizer Inc. Enzon's product-driven strategy includes an extensive drug development program that leverages its proprietary technologies including a Customized Linker Technology PEGylation platform that utilizes customized linkers designed to release compounds at a controlled rate. Enzon also utilizes contract manufacturing opportunities to broaden its revenue base and enhance its organizational productivity. Enzon complements its internal research and development efforts with strategic initiatives. Enzon Inc. has a market cap of $321.5 million; its shares were traded at around $7.12 with and P/S ratio of 1.6.
New Purchase: UltraShort Real Estate ProShares (SRS, Financial)
Carl Icahn initiated holdings in UltraShort Real Estate ProShares. His purchase prices were between $54.29 and $99.32, with an estimated average price of $66.6. The impact to his portfolio due to this purchase was 0.05%. His holdings were 24,000 shares as of 03/31/2009.
size=14px]Reduced: The Williams Companies Inc. (WMB, Financial)[/size]
Carl Icahn reduced to his holdings in The Williams Companies Inc. by 97.94%. His sale prices were between $9.73 and $15.68, with an estimated average price of $12.9. The impact to his portfolio due to this sale was -0.18%. Carl Icahn still held 360,000 shares as of 03/31/2009.
Williams Companies moves manages and markets a variety of energy products including natural gas liquid hydrocarbons petroleum and electricity. Based in Tulsa Oklahoma Williams' operations span the energy value chain from wellhead to burner tip. The Williams Companies Inc. has a market cap of $9.39 billion; its shares were traded at around $16.21 with a P/E ratio of 9 and P/S ratio of 0.8. The dividend yield of The Williams Companies Inc. stocks is 2.8%. The Williams Companies Inc. had an annual average earning growth of 5% over the past 5 years.
Reduced: Endo Pharmaceuticals Holdings Inc. (ENDP, Financial)
Carl Icahn reduced to his holdings in Endo Pharmaceuticals Holdings Inc. by 25.03%. His sale prices were between $16.79 and $23.52, with an estimated average price of $20.3. The impact to his portfolio due to this sale was -0.21%. Carl Icahn still held 1,129,126 shares as of 03/31/2009.
Endo Pharmaceuticals Holdings Inc. through its wholly owned subsidiaries Endo Pharmaceuticals Inc. and Endo Inc. is engaged in the research development sales and marketing of branded and generic prescription pharmaceuticals used primarily for the treatment and management of pain. Endo Pharmaceuticals Holdings Inc. has a market cap of $1.94 billion; its shares were traded at around $16.6 with a P/E ratio of 6.6 and P/S ratio of 1.5. Endo Pharmaceuticals Holdings Inc. had an annual average earning growth of 25.5% over the past 5 years.
Sold Out: Anadarko Petroleum Corp. (APC, Financial)
Carl Icahn sold out his holdings in Anadarko Petroleum Corp.. His sale prices were between $32.98 and $41.67, with an estimated average price of $37.9. The impact to his portfolio due to this sale was less than 0.01%.
Anadarko Petroleum Corporation is one of the world's largest independentoil and gas exploration and production companies. Majority of the company'stotal proved reserves are located in the U.S. primarily in the mid-continent (Kansas Oklahoma and Texas) area offshore in the Gulf of Mexico and in Alaska. Most of the company's production is domestic and the remainder is from Algeria. The company also owns and operates gas gathering systems in its U.S. core producing areas. Anadarko Petroleum Corp. has a market cap of $21.14 billion; its shares were traded at around $45.06 with a P/E ratio of 15.1 and P/S ratio of 1.3. The dividend yield of Anadarko Petroleum Corp. stocks is 0.8%. Anadarko Petroleum Corp. had an annual average earning growth of 28% over the past 10 years. GuruFocus rated Anadarko Petroleum Corp. the business predictability rank of 3.5-star.
Sold Out: FORESTAR RE GROUP (FOR, Financial)
Carl Icahn sold out his holdings in FORESTAR RE GROUP. His sale prices were between $6.1 and $12.09, with an estimated average price of $8.7. The impact to his portfolio due to this sale was less than 0.01%.
Forestar Group Inc. formerly known as Forestar Real Estate Group Inc. operates in two business segments: real estate and natural resources. The real estate segment owns directly or through ventures real estate. The natural resources segment manages acres of oil and gas mineral interests. In addition the company also sells wood fiber from its land primarily located in Georgia and leases land for recreational uses. FORESTAR RE GROUP has a market cap of $444.3 million; its shares were traded at around $12.39 with a P/E ratio of 53.9 and P/S ratio of 2.8.
Sold Out: TempleInland Inc. (TIN, Financial)
Carl Icahn sold out his holdings in TempleInland Inc.. His sale prices were between $2.52 and $5.56, with an estimated average price of $4.5. The impact to his portfolio due to this sale was less than 0.01%.
Temple-Inland Inc. is a holding company that conducts all of its operations through its subsidiaries. The business of Temple-Inland is divided among three groups: Paper Group Building Products Group and Financial Services Group. Containerboard is the largest segment of the paper market. Containerboard is used to make corrugated packaging. The demand for building products is driven by new housing and repair and remodeling markets. In financial services they are pursuing a high touch high service strategy. TempleInland Inc. has a market cap of $1.25 billion; its shares were traded at around $11.72 with a P/E ratio of 26.1 and P/S ratio of 0.3. The dividend yield of TempleInland Inc. stocks is 3.4%. TempleInland Inc. had an annual average earning growth of 2.9% over the past 10 years.
Sold Out: AMICUS THERAPEUTICS, INC. (FOLD, Financial)
Carl Icahn sold out his holdings in AMICUS THERAPEUTICS, INC.. His sale prices were between $7.26 and $12.27, with an estimated average price of $8.9. The impact to his portfolio due to this sale was less than 0.01%.
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells leading to improved protein folding and trafficking and increased activity. Amicus is initially targeting lysosomal storage disorders which are severe chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. AMICUS THERAPEUTICS, INC. has a market cap of $170.1 million; its shares were traded at around $7.51 with and P/S ratio of 11.4.
Sold Out: LIFE TECHNOLOGIES CORPORATION (LIFE)
Carl Icahn sold out his holdings in LIFE TECHNOLOGIES CORPORATION. His sale prices were between $23.24 and $32.66, with an estimated average price of $28.4. The impact to his portfolio due to this sale was less than 0.01%.
Life Technologies Corporation is a global biotechnology tools company. The company provides product and services that support researchers to accelerate scientific exploration driving to discoveries and developments that make life better. Life Technologies customers do their work across the biological spectrum working to advance personalized medicine regenerative science molecular diagnostics agricultural and environmental research and 21st century forensics. The company has a presence in more than 100 countries and possesses a rapidly growing intellectual property estate of over 3600 patents and exclusive licenses.Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. LIFE TECHNOLOGIES CORPORATION has a market cap of $6.53 billion; its shares were traded at around $37.56 with a P/E ratio of 13.4 and P/S ratio of 4.1.
Carl Icahn buys UltraShort Real Estate ProShares, sells Anadarko Petroleum Corp., TempleInland Inc., FORESTAR RE GROUP, AMICUS THERAPEUTICS, INC., LIFE TECHNOLOGIES CORPORATION during the 3-months ended 03/31/2009, according to the most recent filings of his investment company, Icahn Capital Management LP.
New Purchases: SRS,
Added Positions: AMLN, ENZN, LGF, TTWO,
Reduced Positions: ENDP, WMB,
Sold Out: APC, FOLD, FOR, LIFE, TIN,
For the details of Carl Icahn's stock buys and sells, go to the Link Here
This is the sector weightings of Carl Icahn's portfolio:
| Technology |  54.8% |
|---|---|
| Financials | 0.7% |
| Consumer Services | 3.5% |
| Health Care | 40.2% |
| Consumer Goods | 0.7% |
| Oil & Gas | 0.2% |
These are the top 5 holdings of Carl Icahn
- Yahoo! Inc. (YHOO) - 60,452,099 shares, 33.11% of the total portfolio
- Biogen Idec Inc (BIIB) - 12,860,205 shares, 28.82% of the total portfolio
- Motorola Inc. (MOT) - 119,790,447 shares, 21.67% of the total portfolio
- Amylin Pharmaceuticals Inc. (AMLN) - 12,971,328 shares, 6.52% of the total portfolio
- Lions Gate Entertainment Corp. (LGF) - 13,432,899 shares, 2.9% of the total portfolio
Carl Icahn added to his holdings in Lions Gate Entertainment Corp. by 49.93%. His purchase prices were between $4.2 and $5.8, with an estimated average price of $5.2. The impact to his portfolio due to this purchase was 0.97%. His holdings were 13,432,899 shares as of 03/31/2009.
Lions Gate Entertainment is a leading diversified independent producer and distributor of motion pictures home entertainment television programming animation and video-on-demand content. Lions Gate Entertainment Corp. has a market cap of $618.6 million; its shares were traded at around $5.34 with and P/S ratio of 0.4.
Added: Amylin Pharmaceuticals Inc. (AMLN, Financial)
Carl Icahn added to his holdings in Amylin Pharmaceuticals Inc. by 13.52%. His purchase prices were between $8.41 and $13.44, with an estimated average price of $11.2. The impact to his portfolio due to this purchase was 0.78%. His holdings were 12,971,328 shares as of 03/31/2009.
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes SYMLIN injection and BYETTA injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego California with over one thousand five hundred employees nationwide. Amylin Pharmaceuticals Inc. has a market cap of $1.58 billion; its shares were traded at around $11.23 with and P/S ratio of 1.9.
Added: TakeTwo Interactive Software Inc. (TTWO, Financial)
Carl Icahn added to his holdings in TakeTwo Interactive Software Inc. by 270.97%. His purchase prices were between $6.19 and $8.57, with an estimated average price of $7.4. The impact to his portfolio due to this purchase was 0.53%. His holdings were 2,007,445 shares as of 03/31/2009.
Take-Two Interactive Software Inc. is a leading worldwide developer publisher and distributor of interactive software games. The company's software operates on multimedia personal computers and video game console platforms. They are one of the largest distributors of interactive software games in the United States and one of the top publishers of interactive software games in Europe. TakeTwo Interactive Software Inc. has a market cap of $751 million; its shares were traded at around $9.35 with a P/E ratio of 7.4 and P/S ratio of 0.5.
Added: Enzon Inc. (ENZN, Financial)
Carl Icahn added to his holdings in Enzon Inc. by 14.61%. His purchase prices were between $5.27 and $7.1, with an estimated average price of $6.1. The impact to his portfolio due to this purchase was 0.09%. His holdings were 2,816,861 shares as of 03/31/2009.
Enzon Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases. Enzon's specialized sales force markets ABELCET ONCASPAR ADAGEN and DEPOCYT in the United States. In addition Enzon also receives royalties on sales of PEG-INTRON marketed by Schering-Plough Corporation and MACUGEN marketed by OSI Pharmaceuticals and Pfizer Inc. Enzon's product-driven strategy includes an extensive drug development program that leverages its proprietary technologies including a Customized Linker Technology PEGylation platform that utilizes customized linkers designed to release compounds at a controlled rate. Enzon also utilizes contract manufacturing opportunities to broaden its revenue base and enhance its organizational productivity. Enzon complements its internal research and development efforts with strategic initiatives. Enzon Inc. has a market cap of $321.5 million; its shares were traded at around $7.12 with and P/S ratio of 1.6.
New Purchase: UltraShort Real Estate ProShares (SRS, Financial)
Carl Icahn initiated holdings in UltraShort Real Estate ProShares. His purchase prices were between $54.29 and $99.32, with an estimated average price of $66.6. The impact to his portfolio due to this purchase was 0.05%. His holdings were 24,000 shares as of 03/31/2009.
size=14px]Reduced: The Williams Companies Inc. (WMB, Financial)[/size]
Carl Icahn reduced to his holdings in The Williams Companies Inc. by 97.94%. His sale prices were between $9.73 and $15.68, with an estimated average price of $12.9. The impact to his portfolio due to this sale was -0.18%. Carl Icahn still held 360,000 shares as of 03/31/2009.
Williams Companies moves manages and markets a variety of energy products including natural gas liquid hydrocarbons petroleum and electricity. Based in Tulsa Oklahoma Williams' operations span the energy value chain from wellhead to burner tip. The Williams Companies Inc. has a market cap of $9.39 billion; its shares were traded at around $16.21 with a P/E ratio of 9 and P/S ratio of 0.8. The dividend yield of The Williams Companies Inc. stocks is 2.8%. The Williams Companies Inc. had an annual average earning growth of 5% over the past 5 years.
Reduced: Endo Pharmaceuticals Holdings Inc. (ENDP, Financial)
Carl Icahn reduced to his holdings in Endo Pharmaceuticals Holdings Inc. by 25.03%. His sale prices were between $16.79 and $23.52, with an estimated average price of $20.3. The impact to his portfolio due to this sale was -0.21%. Carl Icahn still held 1,129,126 shares as of 03/31/2009.
Endo Pharmaceuticals Holdings Inc. through its wholly owned subsidiaries Endo Pharmaceuticals Inc. and Endo Inc. is engaged in the research development sales and marketing of branded and generic prescription pharmaceuticals used primarily for the treatment and management of pain. Endo Pharmaceuticals Holdings Inc. has a market cap of $1.94 billion; its shares were traded at around $16.6 with a P/E ratio of 6.6 and P/S ratio of 1.5. Endo Pharmaceuticals Holdings Inc. had an annual average earning growth of 25.5% over the past 5 years.
Sold Out: Anadarko Petroleum Corp. (APC, Financial)
Carl Icahn sold out his holdings in Anadarko Petroleum Corp.. His sale prices were between $32.98 and $41.67, with an estimated average price of $37.9. The impact to his portfolio due to this sale was less than 0.01%.
Anadarko Petroleum Corporation is one of the world's largest independentoil and gas exploration and production companies. Majority of the company'stotal proved reserves are located in the U.S. primarily in the mid-continent (Kansas Oklahoma and Texas) area offshore in the Gulf of Mexico and in Alaska. Most of the company's production is domestic and the remainder is from Algeria. The company also owns and operates gas gathering systems in its U.S. core producing areas. Anadarko Petroleum Corp. has a market cap of $21.14 billion; its shares were traded at around $45.06 with a P/E ratio of 15.1 and P/S ratio of 1.3. The dividend yield of Anadarko Petroleum Corp. stocks is 0.8%. Anadarko Petroleum Corp. had an annual average earning growth of 28% over the past 10 years. GuruFocus rated Anadarko Petroleum Corp. the business predictability rank of 3.5-star.
Sold Out: FORESTAR RE GROUP (FOR, Financial)
Carl Icahn sold out his holdings in FORESTAR RE GROUP. His sale prices were between $6.1 and $12.09, with an estimated average price of $8.7. The impact to his portfolio due to this sale was less than 0.01%.
Forestar Group Inc. formerly known as Forestar Real Estate Group Inc. operates in two business segments: real estate and natural resources. The real estate segment owns directly or through ventures real estate. The natural resources segment manages acres of oil and gas mineral interests. In addition the company also sells wood fiber from its land primarily located in Georgia and leases land for recreational uses. FORESTAR RE GROUP has a market cap of $444.3 million; its shares were traded at around $12.39 with a P/E ratio of 53.9 and P/S ratio of 2.8.
Sold Out: TempleInland Inc. (TIN, Financial)
Carl Icahn sold out his holdings in TempleInland Inc.. His sale prices were between $2.52 and $5.56, with an estimated average price of $4.5. The impact to his portfolio due to this sale was less than 0.01%.
Temple-Inland Inc. is a holding company that conducts all of its operations through its subsidiaries. The business of Temple-Inland is divided among three groups: Paper Group Building Products Group and Financial Services Group. Containerboard is the largest segment of the paper market. Containerboard is used to make corrugated packaging. The demand for building products is driven by new housing and repair and remodeling markets. In financial services they are pursuing a high touch high service strategy. TempleInland Inc. has a market cap of $1.25 billion; its shares were traded at around $11.72 with a P/E ratio of 26.1 and P/S ratio of 0.3. The dividend yield of TempleInland Inc. stocks is 3.4%. TempleInland Inc. had an annual average earning growth of 2.9% over the past 10 years.
Sold Out: AMICUS THERAPEUTICS, INC. (FOLD, Financial)
Carl Icahn sold out his holdings in AMICUS THERAPEUTICS, INC.. His sale prices were between $7.26 and $12.27, with an estimated average price of $8.9. The impact to his portfolio due to this sale was less than 0.01%.
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells leading to improved protein folding and trafficking and increased activity. Amicus is initially targeting lysosomal storage disorders which are severe chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. AMICUS THERAPEUTICS, INC. has a market cap of $170.1 million; its shares were traded at around $7.51 with and P/S ratio of 11.4.
Sold Out: LIFE TECHNOLOGIES CORPORATION (LIFE)
Carl Icahn sold out his holdings in LIFE TECHNOLOGIES CORPORATION. His sale prices were between $23.24 and $32.66, with an estimated average price of $28.4. The impact to his portfolio due to this sale was less than 0.01%.
Life Technologies Corporation is a global biotechnology tools company. The company provides product and services that support researchers to accelerate scientific exploration driving to discoveries and developments that make life better. Life Technologies customers do their work across the biological spectrum working to advance personalized medicine regenerative science molecular diagnostics agricultural and environmental research and 21st century forensics. The company has a presence in more than 100 countries and possesses a rapidly growing intellectual property estate of over 3600 patents and exclusive licenses.Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. LIFE TECHNOLOGIES CORPORATION has a market cap of $6.53 billion; its shares were traded at around $37.56 with a P/E ratio of 13.4 and P/S ratio of 4.1.
